Search results
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks via Yahoo Finance· 7 months agoVYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a...
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 4 weeks agoVYNE Therapeutics (VYNE) delivered earnings and revenue surprises of 37.50% and 2%, respectively,...
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
Zacks via Yahoo Finance· 3 months agoVYNE Therapeutics Inc. (VYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing...
VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. via Yahoo Finance· 2 months agoThere's no doubt that money can be made by owning shares of unprofitable businesses. For example,...
VYNE Gains on Preclinical Data for IPF Candidate
Zacks via Yahoo Finance· 1 year agoVYNE Therapeutics VYNE gained almost 42.5% on Apr 19. It did so after announcing promising preclinical data on its new pan-BET inhibitor, VYN201, for...
Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock
Simply Wall St. via Yahoo Finance· 4 months agoGenerally, when a single insider buys stock, it is usually not a big deal. However, when several...
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully
Simply Wall St. via Yahoo Finance· 1 year agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
Further weakness as VYNE Therapeutics (NASDAQ:VYNE) drops 20% this week, taking one-year losses to...
Simply Wall St. via Yahoo Finance· 1 year agoEven the best stock pickers will make plenty of bad investments. And unfortunately for VYNE...
VYNE Therapeutics receives FDA approval for trial of VYN202
Clinical Trials Arena via Yahoo Finance· 4 weeks agoUS-based biopharmaceutical company VYNE Therapeutics has received US Food and Drug Administration...
VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 3 months agoVYNE Therapeutics (NASDAQ:VYNE) Full Year 2023 Results Key Financial Results Net loss: US$27.9m...